COLOPLAST B A/SCC

COLOPLAST B A/S

725.2DKKD
−0.8−0.11%
At close at 15:59 GMT
DKK
No trades
See on Supercharts

COLO_B fundamentals

Key facts

Market capitalization‪163.35 B‬DKK
Founded1957
Employees (FY)‪16.64 K‬
CEOKristian Villumsen
About

Coloplast A/S engages in the developing, manufacture, and markets medical products. It operates through the following segments: Chronic Care, Voice and Respiratory Care, Interventional Urology, Advanced Wound Dressings, and Biologics. The Chronic Care segment covers the sale of ostomy care products and continence care products. The Voice and Respiratory Care segment refers to the sale of laryngectomy and tracheostomy products. The Interventional Urology segment includes the sale of urological products, including disposable products. The Advanced Wound Dressings segment focuses on the sale of wound and skin care products. The Biologics segment represents a new segment covering the sale of tissue-based products. The company was founded by Aage Louis-Hansen and Johanne Louise-Hansen in 1954 and is headquartered in Humlebaek, Denmark.

Ownership
‪‪207.37 M‬‬
Free Float shares
‪‪142.09 M‬‬ (68.52%)
Closely held shares
‪‪65.27 M‬‬ (31.48%)
Free Float shares
‪‪142.09 M‬‬ (68.52%)
Closely held shares
‪‪65.27 M‬‬ (31.48%)
Capital structure
Market cap
‪‪163.35 B‬‬
Debt
‪‪19.76 B‬‬
Cash & equivalents
‪‪906.00 M‬‬
Enterprise value
‪‪182.20 B‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪163.35 B‬‬
Price to earning ratio (P/E)
33.44x
Price to sales ratio (P/S)
5.96x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
33.44x
Price to sales ratio (P/S)
5.96x
Valuation ratios
‪0.00‬
‪2.10‬
‪4.20‬
‪6.30‬
‪8.40‬
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪11.00‬
‪22.00‬
‪33.00‬
‪44.00‬
P/E
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪10.0%‬
‪12.5%‬
‪15.0%‬
‪17.5%‬
‪20.0%‬
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪‪2.00 B‬‬
‪‪4.00 B‬‬
‪‪6.00 B‬‬
‪‪8.00 B‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪0.00‬
‪‪2.00 B‬‬
‪‪4.00 B‬‬
‪‪6.00 B‬‬
‪‪8.00 B‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪0.00‬
‪‪2.00 B‬‬
‪‪4.00 B‬‬
‪‪6.00 B‬‬
‪‪8.00 B‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2024
Chronic Care
Advanced Wound Dressings
Interventional Urology
Voice and Respiratory Care
Biologics
By country
Period: 2024
Other - European Markets
United States
Other - Emerging Markets
United Kingdom
France
Other Developed Markets
Denmark

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
Q2 '24
Q3 '24
Q4 '24
Q1 '25
Q2 '25
‪0.00‬
‪‪2.00 B‬‬
‪‪4.00 B‬‬
‪‪6.00 B‬‬
‪‪8.00 B‬‬
Actual
Estimate
Earnings
Next:May 6, 2025
Q2 '24
Q3 '24
Q4 '24
Q1 '25
Q2 '25
‪0.00‬
‪1.60‬
‪3.20‬
‪4.80‬
‪6.40‬
Actual
Estimate

Dividends

Dividend yield, history and sustainability

Dividend summary
101.32%
Payout ratio (TTM)
Dividend yield TTM
3.03%
Last payment
17.00
Last ex-date
Dec 6, 2024
Dividend history
‪1.50%‬
‪1.85%‬
‪2.20%‬
‪2.55%‬
‪2.90%‬
2020
2021
2022
2023
2024
‪0.00‬
‪6.00‬
‪12.00‬
‪18.00‬
‪24.00‬
Dividends per share (FY)
Dividend yield (FY) %

Financial health

Financial position and solvency of the company

Debt level and coverage
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪‪−9.00 B‬‬
‪0.00‬
‪‪9.00 B‬‬
‪‪18.00 B‬‬
‪‪27.00 B‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪10.00 B‬‬
‪‪20.00 B‬‬
‪‪30.00 B‬‬
‪‪40.00 B‬‬
Assets
Liabilities